-
Biotech Winners And Losers From ASH Conference
Friday, December 9, 2016 - 12:59pm | 569Read More...The American Society of Hematology (ASH) held its annual December meeting in San Diego, where some of the biggest biotech companies announced clinical trial results, new drug updates and future initiatives. In separate reports, Cantor Fitzgerald analysts mentioned their takes on the announcements...
-
Seattle Genetics No Longer On Goldman Sachs' Sell List
Thursday, September 15, 2016 - 9:48am | 317Read More...Seattle Genetics, Inc. (NASDAQ: SGEN) received a ratings bump from Goldman Sachs to Neutral from Sell after the brokerage revised its Adcetris U.S. sales estimates in 1L Hodgkin's lymphoma (HL) "to reflect greater market penetration per physician diligence." "We model 40 percent penetration (vs. 19...
-
Here's Why Seattle Genetics' Adcetris Is A $2 Billion Product
Wednesday, September 7, 2016 - 10:50am | 370Read More...Morgan Stanley’s Andrew S. Berens believes Seattle Genetics, Inc. (NASDAQ: SGEN)'s Adcetris is a $2 billion products, with growth primarily being driven by higher usage in transplant settings, as well as a move to front-line lymphoma treatment. Berens initiated coverage of the company with an...
-
Jefferies Maintains Buy Rating and $28 PT on Seattle Genetics
Friday, December 2, 2011 - 9:18am | 102Read More...A report from Jefferies reiterates its Buy rating and $28 price target on Seattle Genetics (NASDAQ: SGEN). The report states, “Concerns have been raised by a competitor around post-marketing safety reports to the FDA on Adcetris, including 9 deaths and 1 additional case of PML. We do not view this...
